tdm-180935

TDM‑180935 is a small molecule drug candidate developed by Technoderma Medicines for the topical treatment of atopic dermatitis (AD). It acts as a potent inhibitor of Janus kinase 1 (JAK1) and tyrosine-protein kinase 2 (TYK2), targeting both keratinocyte and T cell-derived pathogenic pathways characteristic of AD. The drug has demonstrated efficacy in preclinical models, favorable toxicology profiles, and minimal systemic absorption in early clinical studies. In Phase IIa trials, topical application showed significant improvements in disease severity scores compared to placebo, with no serious adverse events reported. The drug is being positioned as a potentially safer and more effective alternative to existing topical treatments for atopic dermatitis[1][3][4][5][7].

Other names

TDM180935TDM-180935TDM 180935